乳腺癌分子分型对保乳手术安全性的影响
该回顾性研究纳入618例保乳手术乳腺癌患者,按分子分型分为五组。结果显示HER-2过表达型和三阴性型不增加局部复发和死亡风险,5年无复发生存率和总生存率组间无显著差异,但5年无转移生存率组间有显著差异。
要点
- HER-2过表达型和三阴性型乳腺癌患者可接受保乳治疗,不增加局部复发和死亡风险。
- 5年无复发生存率和总生存率在五组间无显著差异,但5年无转移生存率有显著差异。
- 放疗和淋巴结转移数目是局部复发的独立影响因素,年龄、切缘状态、淋巴结转移数目和分子分型是远处转移的独立影响因素。
核心结论
- HER-2过表达型和三阴性型乳腺癌不会增加保乳患者的局部复发和死亡风险,故可接受保乳治疗。
研究设计与样本
- 回顾性分析2005年8月至2010年8月天津医科大学肿瘤医院618例行保乳手术的乳腺癌患者,按分子分型分为Luminal A型、Luminal B1型、Luminal B2型、HER-2过表达型和三阴性型五组。
主要发现
- 五组患者年龄、肿瘤家族史、TNM分期、钙化、组织学分级、病理类型、内分泌治疗差异有统计学意义(均P<0.05)。
- Luminal A型、Luminal B1型、Luminal B2型、HER-2过表达型和三阴性型的5年无复发生存率分别为99.3%、98.7%、98.4%、94.9%和95.6%,差异无统计学意义(P=0.104)。
- 五组5年无转移生存率分别为97.3%、95.7%、93.7%、87.5%和91.4%,差异有统计学意义(P=0.013)。
- 五组5年总生存率分别为98.6%、97.8%、98.4%、92.5%和95.6%,差异无统计学意义(P=0.153)。
关键数值与推荐
- 多因素分析显示,放疗(HR=0.036,P=0.049)、淋巴结转移数目(HR=10.72,P=0.004)是局部复发的独立影响因素。
- 年龄(HR=0.369,P=0.046)、切缘状态(HR=5.486,P=0.007)、淋巴结转移数目(HR=2.882,P=0.023)、分子分型(HR=5.191,P=0.008)是远处转移的独立影响因素。
- 未显示任何因素为总生存的独立影响因素。
临床怎么用
- HER-2过表达型和三阴性型乳腺癌患者可选择保乳治疗,不增加局部复发和死亡风险。
- 保乳治疗时应关注放疗、淋巴结转移数目、年龄、切缘状态和分子分型对局部复发和远处转移的影响。
局限性
- 本研究为单中心回顾性分析,样本量有限,结论需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the relationship between the breast cancer molecular classification and the prognosis of patients underwent breast-conserving therapy and to discuss the safety of the breast conserving surgery from the choice of operation in terms of breast cancer molecular classification. Methods: Clinical data of 618 patients with breast-conserving therapy in Tianjin Medical University Cancer Institute and Hospital from August 2005 to August 2010 were analyzed retrospectively. According to the molecular classification when breast cancer was diagnosed, patients were subdivided into five groups, including Luminal A, Luminal B1, Luminal B2, HER-2-positive and Triple-negative. Clinicopathological characteristics and prognosis were compared among five groups and the influencing factors of local recurrence, distant metastasis and overall survival were analyzed. Results: Among 618 patients, there were 148 cases Luminal A, 231 cases Luminal B1, 63 cases Luminal B2, 40 cases HER-2-positive and 136 cases Triple-negative. The age, family history, TNM stage, calcification, histological grade, pathological type and response to endocrine therapy of these 5 molecular types of breast cancer patients were significantly different (all P<0.05). The 5-year local regional recurrence-free survival rates of Luminal A, Luminal B1, Luminal B2, HER-2-positive and Triple-negative were 99.3%, 98.7%, 98.4%, 94.9% and 95.9%, respectively, without significant differences (P=0.104). The 5-year distant metastasis-free survival rates of these 5 types were 97.3%, 95.7%, 93.7%, 87.5% and 91.4%, respectively, with significant differences (P=0.013). Moreover, the 5-year overall survival rates of these 5 types were 98.6%, 97.8%, 98.4%, 92.5% and 95.6%, respectively, without significant differences (P=0.153). Multifactor analysis showed that radiotherapy (HR=0.036, P=0.049) and the number of lymph node metastases (HR=10.72, P=0.004) were independent factors of local recurrence of breast cancer patients underwent breast-conserving therapy. The age (HR=0.369, P=0.046), status of surgical margin (HR=5.486, P=0.007), number of lymph node metastases (HR=2.882, P=0.023) and molecular typing (HR=5.191, P=0.008) were independent factors of distant metastasis of above breast cancer patients. None of the factors were found to be independent factors of the overall survival of these breast cancer patients. Conclusions: Breast conserving therapy does not increase the risks of local recurrence and death of HER-2-positive and Triple-negative breast cancer patients. Therefore, breast conserving therapy can be accepted by patients with HER-2-positive and Triple-negative breast cancer. 目的:分析乳腺癌分子分型与保乳治疗乳腺癌患者预后的关系,从分子分型角度探讨保乳手术的安全性问题。 方法:回顾性分析2005年8月至2010年8月天津医科大学肿瘤医院618例行保乳手术的乳腺癌患者,根据分子分型不同分为Luminal A型、Luminal B1型、Luminal B2型、人表皮生长因子受体2(human epidermal growth factor receptor-2, HER-2)过表达型、三阴性型,比较5型患者的临床病理特征及预后,分析局部复发、远处转移和总生存的影响因素。 结果: Luminal A型148例,Luminal B1型231例,Luminal B2型63例,HER-2过表达型40例,三阴性型136例。5种分子分型乳腺癌患者的年龄、肿瘤家族史、TNM分期、钙化、组织学分级、病理类型、内分泌治疗差异有统计学意义(均P<0.05)。Luminal A型、Luminal B1型、Luminal B2型、HER-2过表达型和三阴性型患者的5年无复发生存率分别为99.3%、98.7%、98.4%、94.9%和95.6%,差异无统计学意义(P=0.104);5年无转移生存率分别为97.3%、95.7%、93.7%、87.5%和91.4%,差异有统计学意义(P=0.013);5年总生存率分别为98.6%、97.8%、98.4%、92.5%和95.6%,差异无统计学意义(P=0.153)。多因素分析显示,放疗(HR=0.036,P=0.049)、淋巴结转移数目(HR=10.72,P=0.004)是保乳治疗乳腺癌患者局部复发的独立影响因素,年龄(HR=0.369,P=0.046)、切缘状态(HR=5.486,P=0.007)、淋巴结转移数目(HR=2.882,P=0.023)、分子分型(HR=5.191,P=0.008)是保乳治疗乳腺癌患者远处转移的独立影响因素,未显示任何因素为保乳治疗乳腺癌患者总生存的独立影响因素。 结论: HER-2过表达型和三阴性型乳腺癌不会增加保乳患者的局部复发和死亡风险,故HER-2过表达型和三阴性型乳腺癌患者可接受保乳治疗。.
引用
- Li Y, Mu L, Ruan YX, et al. [The influence of molecular classification of breast cancer on the safety of breast-conserving surgery]. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29860760. doi:10.3760/cma.j.issn.0253-3766.2018.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。